A new study by the Canadian Health Policy Institute (CHPI) sets the facts straight about the cost of patented drugs in Canada. Knowing the truth about drug costs is important. The cost of patented drugs is often cited to justify the regulation of pharmaceutical markets and to restrict public and private insurance coverage of new … Read more
The author of a new article published by the Canadian Health Policy Institute (CHPI) questions the validity of statistics about fatal Adverse Drug Reactions (ADRs) that are commonly cited by those who advocate for increased regulation of new drugs in Canada. It is frequently claimed that 100,000 or more hospitalized patients in the United States … Read more
A new study published by the Canadian Health Policy Institute (CHPI) compares insurance coverage for new medicines between Canada's provincial and federal public drug programs; and between public sector drug programs and the benchmarks currently set in a competitive market by private-sector drug insurance. Using data from Health Canada and IMS Brogan, the study specifically … Read more
A new study published by the Canadian Health Policy Institute (CHPI) challenges alarmist claims that the cost of new drugs is threatening the sustainability of private drug plans. An executive of one of Canada's largest private health insurance companies recently stated that, "The evidence clearly shows that most drug plans, as they exist, are not … Read more
The Canadian Health Policy Institute estimates the potential cost of therapeutic substitution for PPI drugs in Quebec could be $50 to $162 million. Quebec's ministry of health recently announced changes to its reimbursement policy for proton pump inhibitor (PPI) drugs covered under the public prescription drug insurance plan, le regime public d'assurance medicaments (RGAM) du … Read more
